ARVNArvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (P…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Arvinas (ARVN) Q2 2026 Earnings Call Transcript VEPPANU's FDA approval and $50 million Pfizer milestone fuel record net income. | ||
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says Arcus Biosciences (RCUS) Casdatifan therapy for renal cell carcinoma could be launched in 2028 and p | MMT Newswires | |
 Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. | ||
 Arvinas, Inc. Q2 2026 Earnings Call Summary Moby summary of Arvinas, Inc.'s Q2 2026 earnings call | ||
 Arvinas Q2 Earnings Call Highlights Arvinas (NASDAQ:ARVN) said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product wit | ||
 Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates Arvinas (ARVN) delivered earnings and revenue surprises of +1,175.00% and +562.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Is Kymera Therapeutics Poised for a Breakthrough With KT-621? Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline. | ||